Quarterly report · Q1
9776.TEDINET S100RLX2
Period2023-04-01 → 2023-06-30
Filed2023-08-09
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.9bn | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥20.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.9bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥76m | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥132m | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥81m | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥223m | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥74m | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥222m | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥6m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥569m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥78m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥9m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥125m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥16.7bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥16.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥16.2bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.9bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥5.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥10.8bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥10.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.4bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.8bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.7bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥1.72 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥170.53 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.35 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 63.2% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.1% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.3% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-06-30 | ¥18m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-06-30 | ¥18m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥855,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-06-30 | ¥12m |
| jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥1.9bn |
| jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥1.9bn |
| jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥62m |
| jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥2.7bn |
| jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥2.7bn |
| jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥108m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥431m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥265m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥166m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥4m |
| —segment total | revenue | 2023-04-01 → 2023-06-30 | ¥5.1bn |
| —segment total | revenue external | 2023-04-01 → 2023-06-30 | ¥4.9bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥166m |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | ¥166m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-06-30 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-06-30 | ¥4.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥167m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-06-30 | ¥178m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-06-30 | ¥23m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-06-30 | ¥22m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥846,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-06-30 | ¥15m |
| jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥2.1bn |
| jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥2.1bn |
| jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥200m |
| jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥2.5bn |
| jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥2.5bn |
| jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥78m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥376m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥233m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥143m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | −¥3m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥5.0bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥4.9bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥143m |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥275m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥5.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥4.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥144m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥290m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 376
| Item | Context | Value | Unit |
|---|---|---|---|
| Description issued shares voting rights | CurrentQuarterInstant_SharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)札幌臨床検査センター株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)札幌市中央区北３条西18丁目２番地２ | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Notes accounting treatments specific to quarterly financial statements quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Description of nature of differences between profit loss of reportable segments total and quarterly financial statements (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Description of nature of differences between profit loss of reportable segments total and quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |